查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1835285

人类乳突病毒检测市场（按检测类型、技术、适应症和最终用户划分）—2025-2032 年全球预测

Human Papillomavirus Testing Market by Test Type, Technology, Indication, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，人类乳突病毒检测市场将成长 36 亿美元，复合年增长率为 13.97%。

主要市场统计数据
基准年2024年 12.6亿美元
预计2025年 14.4亿美元
预测年份：2032年 36亿美元
复合年增长率（%） 13.97%

策略性地实施临床、技术和营运驱动因素，重塑人类乳突病毒检测和筛检管道

在临床证据、技术成熟度和医疗服务模式变革的推动下，人类乳突病毒检测领域正在经历持续变革时期。临床医生越来越重视高灵敏度的分子方法进行子宫颈癌筛检，而公共卫生计画则强调公平的可近性和简化的病患管道。同时，照护现场设计和自我管理模式的创新正在降低检测门槛，并在基层医疗和社区中创造新的接触点。

因此，实验室和设备开发商面临新的压力，需要将平台灵活性、通量和单次检测成本的经济性与不断变化的支付方期望和诊断指南相协调。随着趋势的融合，整个生态系统的相关人员（製造商、临床实验室、医疗保健系统和政策制定者）​​必须协调短期营运需求和长期策略投资。在此背景下，定序诊断和数位PCR方法的兴起提高了诊断准确性，但也需要在生物资讯学和监管策略方面进行协调一致的投资。

因此，决策者应将当前的转变视为一个曲折点，而非一个短暂的周期。透过整合临床证据、以使用者为中心的设计和弹性供应链实践，组织可以定位其检测解决方案，使其不仅能够满足当前的临床需求，还能在不同的医疗环境中实现可扩展、可持续的筛检计画。这种采用是构成本分析其余部分的核心驱动力和约束框架，凸显了技术、临床管道和打入市场策略之间进行有意识协调的必要性。

深入分析技术成熟度、检测分散化、数据整合和护理路径调整，这些因素正在重塑整个医疗保健系统的 HPV 检测服务

HPV检测领域正沿着几个相互依存的轴心发生变化，这些轴心共同构成了诊断和护理服务的重新定位。首先，随着指南机构建议采用高灵敏度方法进行初步筛检，分子检测已成为当务之急。这种转变推动了对基于PCR的平台和定序方法的需求，这些平台和方法可在不同类型的检体中提供强大的分析效能。其次，从自采集试剂套件到近患者快速诊断，检体筛检和分散式检查检测方面的创新正在透过解决便利性、隐私性和可及性方面的障碍来扩大可及的患者群体。

第三，数位健康工具与实验室资讯系统的整合，使得筛检计画更具凝聚力，其结果能够推动及时的后续追踪和护理协调。从孤立的检测活动转变为持续、可追踪的筛检流程，需要在互通性和资料管治进行投资，这为週转时间和结果清晰度带来了新的期望。第四，公共卫生重点正在从一次性筛检转向连接疫苗接种、筛检和治疗管道的全面预防策略。这种整合凸显了能够分层风险并为精准分流决策提供资讯的检测的重要性。

最后，成本压力和采购动态持续推动模组化平台的发展，以适应多种检测需求和检体类型。总而言之，这些转变有利于灵活的技术、以患者为中心的采集方法，以及将诊断性能与可操作的医疗管道连接的生态系统。对于那些预见这些动态并采取灵活商业化和临床整合计画的相关人员来说，持续的转型将为改善病患治疗效果和差异化市场定位铺平道路。

对 2025 年关税变化如何改变整个诊断相关人员的供应链弹性、筹资策略和监管规划进行实际评估。

诸如美国2025年实施的关税调整等政策措施，对HPV检测生态系统产生了复杂且累积的影响，其影响远超简单的成本调整。依赖全球供应链供应试剂、塑胶製品和仪器组件的製造商面临投入成本和物流的直接压力。为此，许多供应商加快了区域筹资策略，并锁定了二级供应商，以保持生产的连续性。这些战术性调整减少了对单一来源的依赖，但需要在验证、品质监督和监管文件方面进行短期投资。

因此，实验室和采购团队透过长期合约、批量承诺和多年期服务协议寻求价值，同时应对某些进口耗材的标价上涨。此外，关税引发了製造商和付款人之间关于单位定价永续性以及平衡成本和临床影响的基本契约必要性的对话。重要的是，监管机构明确了诊断套件和定序试剂的分类和进口要求，迫使企业更新其合规蓝图并调整上市时间表。

从战略角度来看，那些积极实现物流多元化、投资国内或近岸製造伙伴关係并重新设计包装和运输布局的公司，在关税环境下表现良好。然而，规模较小的诊断开发商和独立实验室由于谈判筹码有限且资本储备薄弱，面临不成比例的负担。从中期来看，我们认为这些动态将重新调整供应商集中度，加速製造商之间的整合，并刺激创新，从而减少对受关税影响的投入的依赖，同时保持分析性能和临床效用。

详细的細項分析揭示了测试类型、核心技术、临床适应症和最终用户偏好如何决定采用优先顺序和操作要求

細項分析揭示了检测类型、基础技术、临床适应症和最终用户偏好如何影响产品设计、采用通路和营运优先顺序。按类型分类的检测包括细胞学方法（传统涂片和液基细胞学）、基于PCR和定序的分子检测，以及照护现场和自我管理用例的快速检测方法。这些类别涵盖了从基于形态学的筛检到高灵敏度核酸检测的频谱，每个类别对检体处理、操作人员技能和后续临床可行性都有不同的要求。

支援检测类型的技术细分凸显了杂交捕获方法与PCR和定序平台协同作用。对于PCR而言，数位PCR和即时PCR之间的差异会影响检测极限、定量和通量的最佳化；而对于定序而言，差异在于扩展多重基因组解析度的下一代方法与可用于标靶确认和变异表征的桑格法之间的差异。这些技术选择会影响仪器占地面积、工作流程自动化和生物资讯需求，实验室在选择系统时必须对此进行规划。

细胞学和分子标记物联合检测方法涵盖高风险族群和常规族群。主要筛检管道依年龄层分层，区分适用于21-29岁年轻人及30岁以上族群的筛检策略。每种适应症都有不同的敏感性-特异性权衡，并影响报销谈判。

最后，终端用户细分概述了检测的执行地点以及结果如何转化为医疗服务。诊所涵盖基层医疗和专科诊所，对设备规模、训练和病患处理量均有限制。医院包括私立和公立系统，其采购週期、认证要求和中心实验室能力各不相同。实验室本身也分为院内实验室和独立实验室，这会影响规范经济、发布网路和投资期限。整合这些细分市场，使开发人员和买家能够根据临床工作流程的实际情况和付款人的期望，调整产品功能、定价和实施支援。

全面了解区域医疗保健系统成熟度、采购实务和基础设施的差异如何影响全球市场 HPV 检测的采用和实施

区域动态对侦测采用、供应链配置和监管管道有着显着影响，在美洲、欧洲、中东和非洲以及亚太地区呈现不同的模式。在美洲，成熟的筛检项目、先进的实验室基础设施以及不断发展的支付模式有利于采用高灵敏度的分子检测平台。因此，相关人员必须调整其筛检策略，以因应集中式大容量侦测和分散式医疗点的需求。

在欧洲、中东和非洲，监管协调工作和区域采购机制影响着器械註册和价格谈判，这为製造商创造了复杂的环境，他们必须应对每个国家的卫生技术评估流程。该地区许多市场的公共预算有限，实验室能力波动，这为低成本、可靠的分子检测以及本地化生产和培训的伙伴关係创造了机会。将计画过渡到有组织的筛检和整合疫苗宣传活动通常需要卫生署和临床网路之间的密切合作。

亚太地区市场成熟度参差不齐，从拥有先进实验室网路的高度都市区，到注重可扩展且价格合理的检测解决方案的新兴市场，不一而足。私人医疗服务的快速成长，加上基因组学和定序基础设施投资的不断增加，正在推动高性能实验室平台和创新照护现场诊断技术的普及。在所有地区，跨境供应链、临床指南的协调以及数位化医疗赋能将决定检测创新如何有效转化为更完善的全民筛检。

深入的竞争分析，展示平台提供者、试剂供应商、生物资讯公司和实验室网路如何推动差异化价值和伙伴关係主导的市场进入

HPV检测领域的竞争动态由许多知名诊断製造商、新兴分子创新者、试剂和耗材供应商以及专业服务供应商共同塑造。大型平台供应商利用其已安装的仪器和整合试剂模型来创造经常性收益，并透过互联服务和数据分析扩展其提案。相较之下，快速分子分析和定序专家则凭藉标靶检测、快速检验週期和以使用者为中心的设计脱颖而出，这些设计旨在满足小众临床工作流程和服务不足地区的需求。

试剂供应商和试剂盒製造商发挥至关重要的作用，因为检测性能和供应的连续性取决于可靠的耗材和经过验证的供应链。同时，软体和生物资讯供应商也变得越来越具有战略意义，他们提供检验层，将原始分子数据转化为临床可操作的报告和工作流程自动化。独立实验室和联网诊断服务供应商也在透过整合检测量、优化参考工作流程以及协商反映通量效率的价格来发挥市场影响力。

设备原始设备製造商 (OEM) 与检体采集创新者之间、临床实验室与付费方资助的筛检之间以及诊断公司与区域分销商之间的策略伙伴关係，对于市场渗透至关重要。此外，监管敏锐度和本地市场知识仍然是差异化因素。积极与医疗机构合作、投资临床证据产生并支持实施训练的公司，往往能够加速采用。最终，这一切都取决于能否将强大的分析性能与切实可行的实施支援相结合，以应对不同医疗机构的物流现实。

为领导者提供切实可行的建议，以协调产品灵活性、分散测试、弹性供应链和证据生成，从而加速采用和影响

为了抓住HPV检测领域的新机会，产业领导者应采取多管齐下的策略，将技术蓝图、供应链弹性和临床整合结合起来。首先，优先考虑支援多种检测化学方法和检体类型的平台灵活性，使客户能够整合工作流程并降低总体拥有成本。这种方法可以降低实验室的采购复杂性，并在临床网路中建立客户黏着度。其次，透过检验自采集试剂套件和低复杂度的照护现场模式，投资分散式检查模式，同时确保与后续通路和电子健康记录的紧密整合。

第三，我们将透过供应商多元化、关键零件近岸外包以及建立库存视觉化系统来预测中断，从而增强供应链的韧性。第四，我们将推行将临床结果数据与卫生经济分析相结合的策略，以产生证据、支持报销讨论并向付款人展示价值。第五，我们将扩展实施服务，包括培训、品质保证和互通性套件，以帮助买家快速做好营运准备并维持认证标准。最后，我们将与公共卫生机构、学术中心和商业实验室建立策略伙伴关係，以促进指南的采用，并扩大最有利于服务不足人口的筛检计画。

透过实施这些建议，组织可以平衡短期营运绩效和长期差异化，确保技术卓越转化为可衡量的临床影响和永续的商业模式。

对混合方法研究的透明描述，该研究结合了二次证据审查、专家访谈、监管分析和三角综合来检验研究结果和建议。

调查方法结合了系统性证据整合、初步定性访谈以及监管和临床指南的三角检验，从而获得可靠的见解。二次研究涵盖同侪审查文献、公共卫生机构指南文件、临床实务指南、器材监管文件和产业新闻稿，旨在建立技术能力、临床管道和政策发展的全面基准。在适当情况下，临床实验室註册库和科学会议论文集提供了关于新型检测方法性能和实施结果的同期证据。

我们的主要研究包括与各领域的专家进行结构化访谈，包括临床实验室技术人员、临床医生、采购负责人和监管专家，以了解他们对营运限制、应用驱动因素和未满足临床需求的现实观点。这些访谈帮助我们制定了技术采用路径、供应链紧急措施和报销动态的方案。我们对数据进行了三角测量，以确保我们的研究结果反映出多种观点，并确保我们的建议既能解决技术可行性问题，又能切实解决实施问题。

我们的分析方法将专家意见的定性编码与主题综合相结合，以识别跨领域趋势。我们的监管和政策分析考虑了分类途径和报销框架，以便在切合实际的市场准入时间表内製定商业策略。最后，我们清楚地记录了调查方法的局限性，以帮助解读：证据的可近性因地区和适应症而异，分子诊断领域的快速创新週期需要定期更新，以保持战术性建议的相关性。

简洁的结论强调需要在技术、供应链、临床证据和实施方面进行策略合作，以实现改善 HPV 筛检结果的承诺。

摘要：HPV检测领域正处于曲折点，临床重点、技术创新和营运现状带来了机会，也带来了复杂性。高灵敏度的分子检测方法和定序能力提高了诊断的清晰度，而分散式、自主管理的检测模式则扩大了服务匮乏人群的覆盖范围。同时，不断变化的采购动态和近期的关税相关压力凸显了供应链韧性和敏捷商业化策略的重要性。

整个生态系统相关人员的成功取决于产品设计与实际工作流程的契合度、对能够证明临床和经济价值的证据进行投资，以及建立能够促进可扩展应用的伙伴关係。随着检测技术的不断发展，将卓越技术与培训、互通性和品质保证等实用支援服务相结合的组织将最有能力影响筛检计画并改善患者预后。最后，我们强调，在技术开发、研发和营运执行过程中采取有意识的协作行动，对于将创新转化为永续的公共卫生效益至关重要。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 居家 HPV检体检测的快速成长将提高服务匮乏女性的筛检覆盖率
  • 将人工智慧影像分析与 HPV DNA 检测相结合，以提高诊断准确性和分类
  • 照护现场快速 HPV 检测平台的进步，支援即时临床决策
  • 扩大多重分子检测，将 HPV 基因分型和其他性行为感染感染检测结合在一次检测中
  • 最新指南建议在国家计画中优先进行 HPV筛检而非细胞学筛检
  • 加强诊断设备製造商和公共卫生机构在社区筛检工作中的合作
  • 基于 CRISPR 的分子诊断技术能够以低成本实现超灵敏、快速的 HPV 检测
  • 人们对 DNA 甲基化等表观遗传生物标记的兴趣日益浓厚，以改善 HPV 阳性患者的风险分层
  • 加大对低成本 HPV 检测的开发投入，以弥补中低收入国家的筛检差距
  • 远端医疗HPV筛检和追踪服务扩大了远距访问和病人参与

第六章 2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 人类乳突病毒检测市场（依检测类型）

  • 细胞学检查
    • 传统的
    • 液体基
  • 分子检测
    • PCR相容
    • 序列已启用
  • 快速检测
    • 照护现场
    • 自我管理

9. 人类乳突病毒检测市场（按技术）

  • 杂交捕获
  • PCR
    • 数位的
    • 即时的
  • 顺序
    • 新一代
    • 桑格

第 10 章。 人类乳突病毒检测市场（按适应症）

  • 联合检查
    • 高风险
    • 常规
  • 初步筛检
    • 21至29岁
    • 30岁或以上
  • 反射测试
    • Asc Us
    • Lsil

第 11 章。 人类乳突病毒检测市场（按最终用户）

  • 诊所
    • 基层医疗
    • 专业
  • 医院
    • 私人的
    • 公共
  • 实验室
    • 医院为基础
    • 独立

12. 人类乳突病毒检测市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 人类乳突病毒检测市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 人类乳突病毒检测市场（按国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Seegene Inc.
    • GlaxoSmithKline PLC
    • Inovio Pharmaceuticals Inc.
    • Thermo Fisher Scientific Inc.
    • Johnson & Johnson
    • Merck Sharp & Dohme Corp.
    • Pfizer Inc.
    • Siemens Healthineers AG
    • Sanofi SA
    • AstraZeneca PLC
    • MedPath
Product Code: MRR-43127F7278E2

The Human Papillomavirus Testing Market is projected to grow by USD 3.60 billion at a CAGR of 13.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.26 billion
Estimated Year [2025] USD 1.44 billion
Forecast Year [2032] USD 3.60 billion
CAGR (%) 13.97%

A strategic introduction to the evolving clinical, technological, and operational drivers reshaping human papillomavirus testing and screening pathways

The landscape of human papillomavirus testing is undergoing a period of sustained transformation driven by clinical evidence, technological maturation, and shifting care delivery models. Clinicians increasingly prioritize high-sensitivity molecular approaches for cervical cancer screening while public health programs emphasize equitable access and streamlined patient pathways. At the same time, innovation in point-of-care designs and self-administered formats is lowering barriers to testing uptake and creating new touchpoints across primary care and community settings.

Consequently, laboratories and device developers face renewed pressure to align platform flexibility, throughput, and cost-per-test economics with evolving payer expectations and diagnostic guidelines. As trends converge, stakeholders across the ecosystem-manufacturers, clinical laboratories, healthcare systems, and policymakers-must reconcile short-term operational demands with longer-term strategic investments. In this context, the rise of sequencing-enabled diagnostics and digital PCR modalities augments diagnostic precision but also requires coordinated investments in bioinformatics and regulatory strategy.

As a result, decision-makers should view current shifts as an inflection point rather than a transient cycle. By integrating clinical evidence, user-centered design, and resilient supply chain practices, organizations can position testing solutions not only to meet present clinical needs but also to enable scalable, sustainable screening programs across diverse care settings. This introduction frames the core drivers and constraints that shape the remainder of the analysis, underscoring the need for deliberate alignment among technology, clinical pathways, and market access strategies.

A thorough analysis of technological maturation, decentralized testing, data integration, and care pathway alignment that is reshaping HPV testing delivery across healthcare systems

The HPV testing landscape is shifting along multiple, interdependent axes that together constitute a transformative reorientation of diagnostics and care delivery. First, molecular testing has stepped to the forefront as guideline authorities increasingly endorse high-sensitivity approaches for primary screening; this change has precipitated demand for PCR-based platforms and sequencing approaches that deliver robust analytic performance across diverse specimen types. Second, innovations in sample collection and decentralized testing-spanning self-sampling kits to near-patient rapid diagnostics-are expanding the pool of reachable patients by addressing convenience, privacy, and access barriers.

Third, the integration of digital health tools and laboratory information systems is enabling more cohesive screening programs where results drive timely follow-up and care coordination. Transitioning from siloed test events to continuous, trackable screening journeys requires investments in interoperability and data governance, and it introduces new expectations for turnaround times and result clarity. Fourth, public health priorities are shifting from episodic screening toward integrated prevention strategies that link vaccination, screening, and treatment pathways; such integration elevates the importance of tests that can stratify risk and inform precision triage decisions.

Finally, cost pressures and procurement dynamics continue to incentivize modular platforms that can serve multiple testing needs and specimen types. Taken together, these shifts favor flexible technologies, patient-centered collection methods, and ecosystems that couple diagnostic performance with actionable care pathways. For stakeholders that anticipate these dynamics and adopt adaptive commercialization and clinical integration plans, the ongoing transformation opens paths to both improved patient outcomes and differentiated market positioning.

A pragmatic assessment of how tariff policy shifts in 2025 have altered supply chain resilience, procurement strategies, and regulatory planning across diagnostic stakeholders

Policy measures such as tariff changes introduced in 2025 in the United States have imparted a complex, cumulative influence on the HPV testing ecosystem that extends beyond simple cost adjustments. Manufacturers that rely on global supply chains for reagents, plasticware, and instrumentation components experienced immediate pressure on input costs and logistics. In response, many suppliers accelerated regional sourcing strategies and qualified secondary suppliers to preserve production continuity. These tactical adjustments reduced single-source dependencies but required near-term investments in validation, quality oversight, and regulatory documentation.

Consequently, laboratories and procurement teams navigated higher list prices for certain imported consumables while simultaneously seeking value through longer-term contracts, volume commitments, and multi-year service agreements. In addition, the tariffs catalyzed conversations between manufacturers and payers about the sustainability of unit pricing and the need for outcome-based contracting that balances cost with clinical impact. Importantly, regulatory interactions compounded the operational picture as agencies clarified classification and import requirements for diagnostic kits and sequencing reagents, prompting firms to update compliance roadmaps and adjust market entry timetables.

From a strategic perspective, organizations that proactively diversified logistics, invested in domestic or near-shore manufacturing partnerships, and re-engineered packaging and transport footprints navigated the tariff environment more successfully. However, smaller diagnostic developers and independent laboratories faced disproportionate strain due to limited negotiating leverage and thinner capital reserves. In the medium term, these dynamics are likely to reshape supplier concentration, accelerate consolidation among manufacturers, and incentivize innovations that reduce reliance on tariff-exposed inputs while preserving analytical performance and clinical utility.

In-depth segmentation analysis revealing how test types, core technologies, clinical indications, and end user settings jointly determine adoption priorities and operational requirements

Segmentation analysis clarifies how choice of test type, underlying technology, clinical indication, and end-user setting shape product design, adoption pathways, and operational priorities. Tests categorized by type include cytology approaches-both conventional smears and liquid-based cytology-molecular assays that comprise PCR-enabled and sequencing-enabled modalities, and rapid formats that serve point-of-care and self-administered use cases. Together these categories reflect a spectrum from morphology-based screening to high-sensitivity nucleic acid detection, and each category imposes distinct requirements for specimen handling, operator skill, and downstream clinical actionability.

Underpinning test types, technology segmentation highlights the role of hybrid capture methods alongside PCR and sequencing platforms. Within PCR, differentiation between digital PCR and real-time PCR carries implications for limit-of-detection, quantitation, and throughput optimization, while sequencing divides into next-generation approaches that scale multiplexed genomic resolution and Sanger methods that retain utility for targeted confirmation and variant characterization. These technological choices affect instrument footprint, workflow automation, and bioinformatics needs that laboratories must plan for when selecting systems.

Clinical indication segmentation reveals divergent testing pathways: co-testing approaches that combine cytology and molecular markers encompass both high-risk and routine contexts; primary screening pathways are stratified by age cohorts, distinguishing younger adults aged 21 to 29 from screening strategies applied to those aged 30 and above; and reflex testing pathways address cytologic ambiguities such as atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions, where reflex algorithms target specific triage thresholds. Each indication imposes different sensitivity and specificity trade-offs and shapes reimbursement conversations.

Finally, end-user segmentation outlines where tests are performed and how results flow into care. Clinics span primary care and specialist settings, imposing constraints on instrument size, training, and patient throughput. Hospitals include both private and public systems with differing procurement cycles, accreditation requirements, and central laboratory capabilities. Laboratories themselves differentiate into hospital-based and independent entities, with implications for economies of scale, referral networks, and investment horizons. Integrating these segmentation lenses enables developers and buyers to align product features, pricing, and implementation support with the realities of clinical workflows and payer expectations.

Comprehensive regional insight into how healthcare system maturity, procurement practices, and infrastructure variation shape HPV testing adoption and implementation across global markets

Regional dynamics exert a strong influence on testing adoption, supply chain configuration, and regulatory pathways, with distinct patterns observable across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established screening programs, a sophisticated laboratory infrastructure, and evolving payer models favor adoption of high-sensitivity molecular platforms, while at the same time disparities in access and rural coverage drive demand for self-collection and point-of-care solutions. Consequently, stakeholders must calibrate commercialization strategies to address both high-volume centralized laboratories and decentralized care venues.

Across Europe, Middle East & Africa, regulatory harmonization efforts and regional procurement mechanisms influence device registration and pricing negotiations, creating a complex environment for manufacturers that must navigate national health technology assessment processes. In many markets within this region, constrained public budgets and variable laboratory capacity create opportunities for lower-cost, robust molecular assays and for partnerships that localize manufacturing and training. Transitioning programs toward organized screening and integrating vaccination campaigns typically require close coordination between ministries of health and clinical networks.

In the Asia-Pacific region, heterogeneous market maturity spans advanced urban centers with cutting-edge laboratory networks to emerging markets prioritizing scalable, affordable testing solutions. Rapid growth in private healthcare delivery, combined with increasing investment in genomics and sequencing infrastructure, supports adoption of both high-throughput laboratory platforms and innovative point-of-care diagnostics. Across all regions, cross-border supply chains, clinical guideline harmonization, and digital health enablement will determine how effectively testing innovations translate into population-level screening improvements.

A detailed competitive analysis showing how platform providers, reagent suppliers, bioinformatics firms, and laboratory networks drive differentiated value and partnership-led market entry

Competitive dynamics within the HPV testing sector are shaped by a mix of established diagnostic manufacturers, emerging molecular innovators, reagent and consumable suppliers, and specialized service providers. Large platform providers leverage installed instrument bases and integrated reagent models to secure recurring revenue and to broaden their value proposition through connected services and data analytics. In contrast, nimble molecular and sequencing specialists differentiate with targeted assays, rapid validation cycles, and user-centric designs that address niche clinical workflows or underserved geographies.

Reagent suppliers and cartridge manufacturers play a crucial role because assay performance and supply continuity hinge on reliable consumables and validated supply chains. Parallel to this, software and bioinformatics vendors are becoming increasingly strategic, offering interpretive layers that translate raw molecular data into clinically actionable reports and workflow automation. Independent laboratories and networked diagnostic service providers also exert market influence by consolidating testing volumes, optimizing reference workflows, and negotiating pricing that reflects throughput efficiencies.

Strategic partnerships-between instrument OEMs and sample collection innovators, between clinical laboratories and payer-sponsored screening initiatives, and between diagnostics firms and regional distributors-are central to market penetration. Additionally, regulatory acumen and local market knowledge remain differentiators; firms that proactively engage with health authorities, invest in clinical evidence generation, and support implementation training often accelerate uptake. Ultimately, success hinges on the ability to combine robust analytical performance with practical implementation support that addresses the logistical realities of diverse care settings.

Actionable recommendations for leaders to align product flexibility, decentralized testing, resilient supply chains, and evidence generation to accelerate adoption and impact

Industry leaders should adopt a multi-pronged strategy that aligns technology roadmaps, supply chain resilience, and clinical integration to capture emerging opportunities in HPV testing. First, prioritize platform flexibility that supports multiple assay chemistries and specimen types so that customers can consolidate workflows and reduce total cost-of-ownership. This approach reduces procurement complexity for laboratories and creates stickiness across clinical networks. Second, invest in decentralized testing models by validating self-collection kits and low-complexity point-of-care formats while ensuring robust linkage to follow-up pathways and electronic health records.

Third, strengthen supply chain resilience through supplier diversification, near-shoring critical components, and building inventory visibility systems that anticipate disruptions. Fourth, pursue evidence-generation strategies that pair clinical outcomes data with health economic analyses to support reimbursement conversations and to demonstrate value to payers. Fifth, expand implementation services-training, quality assurance, and interoperability toolkits-that help buyers achieve rapid operational readiness and maintain accreditation standards. Finally, cultivate strategic partnerships with public health agencies, academic centers, and commercial laboratories to accelerate guideline adoption and to scale screening programs where underserved populations stand to benefit most.

By executing on these recommendations, organizations can balance near-term operational performance with longer-term differentiation, ensuring that technological excellence translates into measurable clinical impact and sustainable commercial models.

Transparent description of mixed-methods research combining secondary evidence review, expert interviews, regulatory analysis, and triangulated synthesis to validate findings and recommendations

The research methodology combines systematic evidence synthesis, primary qualitative interviews, and triangulation of regulatory and clinical guidance to produce robust insights. Secondary research encompassed peer-reviewed literature, public health agency guidance documents, clinical practice guidelines, device regulatory filings, and industry press releases to build a comprehensive baseline of technology capabilities, clinical pathways, and policy developments. Where appropriate, clinical trial registries and scientific conference proceedings provided contemporaneous evidence on emerging assay performance and implementation outcomes.

Primary research included structured interviews with subject matter experts spanning laboratorians, clinicians, procurement officers, and regulatory specialists to capture pragmatic perspectives on operational constraints, adoption drivers, and unmet clinical needs. These interviews informed scenario planning around technology adoption pathways, supply chain contingencies, and reimbursement dynamics. Data triangulation ensured that findings reflected multiple vantage points and that recommendations addressed both technical feasibility and implementation practicality.

Analytical approaches combined qualitative coding of expert input with thematic synthesis to identify cross-cutting trends. Regulatory and policy analyses reviewed classification pathways and reimbursement frameworks to situate commercial strategies within realistic market access timelines. Finally, methodological limitations were documented transparently to inform interpretation: evidence availability varies by region and indication, and rapid innovation cycles in molecular diagnostics require periodic updates to maintain the relevance of tactical recommendations.

A concise conclusion emphasizing the need for strategic alignment across technology, supply chains, clinical evidence, and implementation to realize the promise of improved HPV screening outcomes

In summary, the HPV testing landscape is at an inflection point where clinical priorities, technological innovation, and operational realities converge to create both opportunity and complexity. High-sensitivity molecular approaches and sequencing capabilities offer enhanced diagnostic clarity, while decentralized and self-administered testing formats expand reach to under-screened populations. At the same time, evolving procurement dynamics and recent tariff-related pressures underscore the importance of supply chain resilience and agile commercialization strategies.

For stakeholders across the ecosystem, success depends on aligning product design with real-world workflows, investing in evidence that demonstrates clinical and economic value, and building partnerships that facilitate scalable implementation. As testing technologies continue to evolve, organizations that couple technical excellence with pragmatic support services-training, interoperability, and quality assurance-will stand in the best position to influence screening programs and to improve patient outcomes. The concluding perspective emphasizes that deliberate, coordinated actions across technology development, market access, and operational execution are essential to translate innovation into sustainable public health gains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid growth in at-home self-sampling HPV testing to increase screening coverage among underserved women
  • 5.2. Integration of AI-driven image analysis with HPV DNA testing to enhance diagnostic accuracy and triage
  • 5.3. Advancements in point-of-care rapid HPV testing platforms for immediate clinical decision support
  • 5.4. Expansion of multiplex molecular assays combining HPV genotyping with other STI detection in a single test
  • 5.5. Implementation of guideline updates recommending primary HPV screening over cytology in national programs
  • 5.6. Rising collaboration between diagnostics manufacturers and public health agencies for community screening initiatives
  • 5.7. Emergence of CRISPR-based molecular diagnostics enabling ultra-sensitive rapid HPV detection at lower cost
  • 5.8. Growing focus on epigenetic biomarkers such as DNA methylation for improved risk stratification in HPV positive patients
  • 5.9. Increasing investment in low-cost HPV test development to address screening gaps in low- and middle-income countries
  • 5.10. Telehealth-enabled HPV screening and follow-up services expanding access and patient engagement in remote areas

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Papillomavirus Testing Market, by Test Type

  • 8.1. Cytology Tests
    • 8.1.1. Conventional
    • 8.1.2. Liquid Based
  • 8.2. Molecular Tests
    • 8.2.1. PCR Enabled
    • 8.2.2. Sequencing Enabled
  • 8.3. Rapid Tests
    • 8.3.1. Point Of Care
    • 8.3.2. Self Administered

9. Human Papillomavirus Testing Market, by Technology

  • 9.1. Hybrid Capture
  • 9.2. PCR
    • 9.2.1. Digital
    • 9.2.2. Real Time
  • 9.3. Sequencing
    • 9.3.1. Next Generation
    • 9.3.2. Sanger

10. Human Papillomavirus Testing Market, by Indication

  • 10.1. Co Testing
    • 10.1.1. High Risk
    • 10.1.2. Routine
  • 10.2. Primary Screening
    • 10.2.1. Age 21 To 29
    • 10.2.2. Age 30 And Above
  • 10.3. Reflex Testing
    • 10.3.1. Asc Us
    • 10.3.2. Lsil

11. Human Papillomavirus Testing Market, by End User

  • 11.1. Clinics
    • 11.1.1. Primary Care
    • 11.1.2. Specialist
  • 11.2. Hospitals
    • 11.2.1. Private
    • 11.2.2. Public
  • 11.3. Laboratories
    • 11.3.1. Hospital Based
    • 11.3.2. Independent

12. Human Papillomavirus Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Human Papillomavirus Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Human Papillomavirus Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Seegene Inc.
    • 15.3.2. GlaxoSmithKline PLC
    • 15.3.3. Inovio Pharmaceuticals Inc.
    • 15.3.4. Thermo Fisher Scientific Inc.
    • 15.3.5. Johnson & Johnson
    • 15.3.6. Merck Sharp & Dohme Corp.
    • 15.3.7. Pfizer Inc.
    • 15.3.8. Siemens Healthineers AG
    • 15.3.9. Sanofi S.A.
    • 15.3.10. AstraZeneca PLC
    • 15.3.11. MedPath

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HUMAN PAPILLOMAVIRUS TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HUMAN PAPILLOMAVIRUS TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HUMAN PAPILLOMAVIRUS TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONVENTIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LIQUID BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LIQUID BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LIQUID BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LIQUID BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR ENABLED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR ENABLED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR ENABLED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR ENABLED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR ENABLED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR ENABLED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING ENABLED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING ENABLED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING ENABLED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING ENABLED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING ENABLED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING ENABLED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SELF ADMINISTERED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SELF ADMINISTERED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SELF ADMINISTERED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SELF ADMINISTERED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SELF ADMINISTERED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SELF ADMINISTERED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HYBRID CAPTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HYBRID CAPTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HYBRID CAPTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HYBRID CAPTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY DIGITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY DIGITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY DIGITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY DIGITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY DIGITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY DIGITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REAL TIME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REAL TIME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REAL TIME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REAL TIME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REAL TIME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REAL TIME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY NEXT GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY NEXT GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY NEXT GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY NEXT GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY NEXT GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY NEXT GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SANGER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SANGER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SANGER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SANGER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SANGER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SANGER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HIGH RISK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HIGH RISK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HIGH RISK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HIGH RISK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HIGH RISK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HIGH RISK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ROUTINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ROUTINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ROUTINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ROUTINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ROUTINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ROUTINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 21 TO 29, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 21 TO 29, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 21 TO 29, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 21 TO 29, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 21 TO 29, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 21 TO 29, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 30 AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 30 AND ABOVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 30 AND ABOVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 30 AND ABOVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 30 AND ABOVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 30 AND ABOVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ASC US, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ASC US, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ASC US, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ASC US, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ASC US, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ASC US, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LSIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LSIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LSIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LSIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LSIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LSIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SPECIALIST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SPECIALIST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SPECIALIST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SPECIALIST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SPECIALIST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SPECIALIST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIVATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIVATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIVATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PUBLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PUBLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PUBLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITAL BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITAL BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITAL BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITAL BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITAL BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITAL BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDEPENDENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDEPENDENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDEPENDENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA